DCA Drug Development Company, CardioMetabolics Inc., Encouraged by Intense Public Interest in Dichloroacetate for Treatment Of Cancer

CMI X-11S (DCA intravenous formulation) is the company's lead clinical stage drug product. CMI has secured permission from the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) and from the CDN Therapeutic Product Directorate (TPD) to initiate Phase III clinical trials for cardiac surgery in higher risk geriatric patients. Other potential applications are earlier stage candidates and the company cautions that much work remains to develop them. Although early results are promising, it may take years of research to prove efficacy in humans.

To date, CMI has been granted four Patents from the USPTO (United States Patent & Trademark Office) and has several other patent applications pending. Two of the issued patents relate to DCA, while the other two cover related compounds of DCA. CMI's patent coverage includes the treatment of cardiovascular diseases and metabolic conditions where ischemic or hypoxic conditions present (such as cardiac surgery), as well as the other disease states mentioned above.

CMI is currently undergoing a round of financing and in discussions with strategic drug partners. The company is focused on unlocking the potential of this exciting drug and its related compounds.